Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial - PubMed
5 hours ago
- #Medical Research
- #Pharmaceutical Industry
- #Conflict of Interest
- Disclosures of conflicts of interest from multiple researchers involved in a study, noting financial relationships with various pharmaceutical and healthcare companies.
- Dr Lu received nonfinancial support from Bayer, Boehringer Ingelheim, Abbott, and Cytokinetics, and personal fees from AstraZeneca and Zoll during the study.
- Dr Kosztin reported personal fees from AstraZeneca, Boehringer Ingelheim, Biotronik, Pfizer, Novo Nordisk, and Novartis outside the submitted work.
- Dr Claggett received consulting fees from Alnylam, Cardior, Cardurion, CVRx, Intellia, Rocket, Eli Lilly, and Alexion.
- Dr Pabon received support for conference presentation from Bayer and Cytokinetics outside the submitted work.
- Dr Desai received grants from Bayer, Alnylam, AstraZeneca, Novartis, Pfizer, Intellia Therapeutics, and Alexion for CEC activities, and consulting fees from a wide range of companies.
- Dr Jhund's university received remuneration from Bayer AG, AstraZeneca, Novartis, and Roche Diagnostics for clinical trials; he also has personal fees and grants from other entities.
- Dr Henderson reported personal fees from Bayer AG outside the submitted work.
- Dr Merkely received personal fees from Boehringer Ingelheim, Daiichi Sankyo, Duke Clinical Institute, and Novartis, and grants from Biotronik, Boehringer Ingelheim, Duke Clinical Institute, Eli Lilly, and Novartis.
- Dr Lam reported grants from Novo Nordisk and Roche Diagnostics, consultant fees from multiple companies, and patents through Us2.ai; he is a cofounder and nonexecutive director of Us2.ai.
- Dr Senni received personal fees from Novartis, Merck, MSD, Bayer, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Amgen, Cardurion, Reprieve, and Abbott outside the submitted work.
- Dr Shah received consulting fees from Bayer during the study.
- Dr Voors reported consultant fees and/or research support from AnaCardio, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cardurion, Corteria, Eli Lilly, Merck, Novartis, Novo Nordisk, QT Sense, Rycarma, and Salubris.
- Dr Zannad received steering committee, advisory board, and speaker fees from multiple companies, and holds stock options and ownership in some entities.
- Dr Pitt reported consultant fees from various companies, data safety monitoring board fees, and stock/stock options, along with patents related to drug delivery and organ damage.
- Drs Amarante and Glasauer are full-time employees of Bayer AG.
- Dr McMurray received support from multiple sources including grants, consultant fees, lecture fees, and data safety monitoring board fees, and serves as a director for Global Clinical Trial Partners Ltd.
- Dr Vaduganathan reported research grant support from numerous companies and served on advisory boards or had speaker engagements with others.
- Dr Solomon received grants from Bayer during the study, and additional grants and consulting fees from a wide array of companies, with no other disclosures reported.